CTI BioPharma Corp (NASDAQ:CTIC)(MTA:CTIC) stated on Wednesday that it expects to receive USD10m in milestone payment for TRISENOX from Teva Pharmaceutical Industries Ltd in February 2018.
According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic leukemia.
Under the terms of a prior acquisition agreement for TRISENOX with Teva, CTI BioPharma is eligible to receive up to an additional USD50m in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.
Headquartered in Seattle, Washington, CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial